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resBACKGROUND Prior studies have suggested that women have better outcomes than men after cardiac resynchroni-
zation therapy-deﬁbrillator (CRT-D) implantation.
OBJECTIVES The purpose of this study was to compare mortality after CRT-D implantation by sex, QRS morphology,
and duration.
METHODS Survival curves and covariate adjusted hazard ratios (HR) were used to assess mortality by sex in 31,892
CRT-D patients in the National Cardiovascular Data Registry (NCDR), implantable cardioverter deﬁbrillator (ICD) registry
between 2006 and 2009, with up to 5 years’ follow-up (median 2.9 years, interquartile range: 2.0 to 3.9 years). Patients
were grouped by QRS morphology and 10-ms increments in QRS duration.
RESULTS Among patients with left bundle branch block (LBBB), women had a 21% lower mortality risk than men
(HR: 0.79; 95% CI: 0.74 to 0.84; p < 0.001); however, there was no sex difference in non-LBBB (HR: 0.95; 95% CI: 0.85
to 1.06; p ¼ 0.37). Longer QRS duration was associated with better survival in both sexes with LBBB, but not in patients
without LBBB. Compared with women with LBBB and QRS of 120 to 129 ms, women with LBBB and QRS of 140 to 149 ms
had a 27% lower mortality (HR: 0.73; 95% CI: 0.60 to 0.88; p ¼ 0.001); this difference was 18% in men (HR: 0.82; 95%
CI: 0.71 to 0.93; p ¼ 0.003). Mortality in LBBB and QRS of 150 ms or longer compared with those with LBBB and QRS of
120 to 129 ms was similar between sexes (HR: 0.61 to 0.68; p < 0.001 for women and HR: 0.58 to 0.66; p < 0.001 for
men). Sex interactions within 10-ms groups were not signiﬁcant.
CONCLUSIONS Among patients with LBBB who received CRT-D, mortality is lower in women than men. Additionally,
longer QRS duration in LBBB is associated with better survival in both sexes. In contrast, there is no sex difference in
patients without LBBB, regardless of QRS duration. Further studies should include a non-CRT comparator group to
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888are subjected to potential device complica-
tions (e.g., infection, lead failure/dislodge-
ment) and costs. Therefore, it is important
to identify those patients most likely to
beneﬁt from this therapy.
Although most CRT clinical trials enrolled
patients with a QRS duration of 120 ms or
longer, meta-analyses found that beneﬁt
from CRT is most pronounced in patients
with a left bundle branch block (LBBB) and
QRS of 150 ms or longer (5,6). These obser-
vations are reﬂected in professional society
guidelines, which limit Class I recommen-
dations for CRT to patients with LBBB and
QRS of 150 ms or longer. Patients withLBBB and QRS of 120 to 149 ms and those without
LBBB are categorized as either Class IIa or IIb rec-
ommendations (7).SEE PAGE 895In clinical trials of CRT, women only represent
approximately 20% of patients; therefore, the results
of both the trials and meta-analyses primarily reﬂect
outcomes in men. Nonetheless, previous studies
suggest that beneﬁt from CRT is greater in women
(8–11). This may be due to a combination of reasons,
including that women are more likely to have LBBB
and nonischemic cardiomyopathy, which are both
associated with a better CRT response (12). Further-
more, separate analyses suggest that one-third of
patients with LBBB by conventional electrocardio-
graphic (ECG) criteria may not have true LBBB (13–16).
Because women have a shorter QRS duration than
men in the absence of any conduction disease (17),
they can have a true LBBB at a shorter QRS duration
than men (16). Previous studies suggest that sex-
speciﬁc QRS duration criteria for LBBB predict a bet-
ter response to CRT (18,19).
This study assessed the effect of CRT by sex in a
large real-world CRT-deﬁbrillator (CRT-D) popula-
tion. The objective was to compare long-term mor-
tality outcomes of women and men receiving CRT-D
among different combinations of QRS morphology
and duration.. Piña has received consulting fees/honoraria from Novartis and G
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This study included all patients in the National Car-
diovascular Data Registry (NCDR), implantable car-
dioverter deﬁbrillator (ICD) registry who received a
CRT-D device between January 1, 2006, and Sep-
tember 30, 2009 (n ¼ 178,900). The registry, formed
in 2005 with data collection beginning in 2006, con-
tains data on all ICD and CRT-D implantations from
more than 80% of hospitals in the United States (20).
Patient-level clinical, demographic, and procedural
information was collected using standardized data
elements and deﬁnitions. The NCDR programs use a
multistage data quality process, including quality
checks on submitted data, outlier analysis, and
medical record audits (21). The ICD Registry is used in
more than 1,400 US hospitals, including almost all
centers that implant cardiac rhythm devices (22).
The deﬁned endpoint for this study was time to
death from any cause obtained by linking NCDR reg-
istry ﬁles with the Social Security Death Master File.
Patients were censored if they were alive at the end of
the follow-up period (March 31, 2011). We excluded
patients with a QRS of <120 ms or >220 ms, epicardial
leads, a history of atrial ﬁbrillation, or a prior pace-
maker or ICD; those who received a CRT-D device for
secondary prevention of sudden cardiac death or had
missing data on sex, QRS morphology, or duration;
patients who could not be linked to the Death Master
File; and those who were not admitted to the hospital
for the sole purpose of CRT-D implantation. Prior
pacemaker or ICD (n ¼ 66,122) and hospital admission
for reasons other than CRT-D implantation (n¼ 50,753)
accounted for most of the 147,008 exclusions (82% of
all identiﬁed registry patients). Patients with QRS of
greater than 220 ms were excluded due to the small
number of subjects in this category and uncertainty
about the accuracy of QRS duration measurement.
Patients who were not admitted for the sole purpose of
CRT-D implantation were excluded based on a poten-
tial confounding effect of competing factors for death.
Finally, the study populationwas restricted to patients
without atrial ﬁbrillation, as atrial ﬁbrillation is asso-
ciated with a low rate of biventricular pacing. The U.S.E Healthcare. The mention of commercial products,
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TABLE 1 Patient Characteristics by Sex in the Total and LBBB CRT-D Populations
Total Population LBBB
Women
(n ¼ 11,542)
Men
(n ¼ 20,350)
Women
(n ¼ 9,978)
Men
(n ¼ 14,174)
Demographics
Age (yrs) 68  11 69  11 68  11 69  11
Race
White 9,016 (78) 16,864 (83) 7,869 (79) 11,818 (83)
Black 1,644 (14) 1,894 (9) 1,339 (13) 1,283 (9)
Hispanic 611 (5) 1,049 (5) 526 (5) 722 (5)
Other 271 (2) 543 (3) 244 (2) 351 (2)
Clinical characteristics
LVEF 24%  7% 24%  7% 24%  7% 24%  7%
NYHA functional heart
failure class
I/II 1,431 (12) 2,975 (15) 1,259 (13) 2,140 (15)
III 9,721 (84) 16,697 (82) 8,399 (84) 11,596 (82)
IV 390 (3) 678 (3) 320 (3) 438 (3)
Ischemic cardiomyopathy 4,354 (38) 13,621 (67) 3,441 (34) 8,760 (62)
LBBB 9,978 (86) 14,174 (70)
Non–LBBB 1,564 (14) 6,176 (30)
QRS duration (ms) 154  19 153  21 155  18 157  21
AV conduction
Normal 9,440 (82) 14,150 (70) 8,255 (83) 10,084 (71)
First-degree block 1,979 (17) 5,733 (28) 1,624 (16) 3,823 (27)
Second-/third-degree block 123 (1) 467 (2) 99 (1) 267 (2)
Heart failure duration
No 423 (4) 988 (5) 360 (4) 658 (5)
<3 months 1,104 (10) 2,142 (11) 931 (9) 1,471 (10)
3–9 months 1,988 (17) 3,212 (16) 1,736 (17) 2,271 (16)
>9 months 8,027 (70) 14,008 (69) 6,951 (70) 9,774 (69)
Previous valvular surgery 499 (4) 1,109 (6) 386 (4) 789 (6)
Cerebrovascular disease 1,203 (10) 2,606 (13) 986 (10) 1,733 (12)
Renal failure/dialysis 220 (2) 594 (3) 179 (2) 375 (3)
Diabetes mellitus 4,325 (38) 8,025 (40) 3,617 (36) 5,324 (38)
Hypertension 8,371 (73) 15,405 (76) 7,181 (72) 10,571 (75)
Sodium (mEq/l) 139  3 139  3 139  3 139  3
Blood urea nitrogen (mmol/l) 23  13 25  13 23  12 24  12
Creatinine (mg/dl) 1.2  0.8 1.4  1.0 1.1  0.8 1.4  0.9
Discharge medications
Beta-blockers 10,295 (89) 17,937 (88) 8,921 (89) 12,519 (88)
Angiotensin receptor blockers 2,779 (24) 3,697 (18) 2,423 (24) 2,586 (18)
ACE inhibitors 6,969 (60) 13,366 (66) 6,059 (61) 9,386 (66)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; AV ¼ atrioventricular; CRT-D ¼ cardiac resynchronization therapy
deﬁbrillator; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association.
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889Food and Drug Administration (FDA) Research in
Human Subjects Committee and the Yale University
Human Investigation Committee approved the analysis.
STATISTICAL ANALYSIS. Univariate and multivari-
able adjusted Cox proportional hazards analysis was
used to calculate mortality risks in the total popula-
tion and in groups stratiﬁed by sex, QRS duration, and
QRS morphology (LBBB and non-LBBB [including
right bundle branch block and nonspeciﬁc intraven-
tricular conduction delay]). The clustering of patients
within hospitals was considered in the Cox propor-
tional hazard models by marginal model approach
with the robust sandwich estimate of the covariance.
The proportional hazards assumption was conﬁrmed
by log-log plotting and supremum test. Multivariable
models included adjustments for all covariates in
Table 1 and additionally for syncope, family history of
sudden death, cardiac arrest, ventricular tachycardia,
myocardial infarction, coronary artery bypass graft,
percutaneous coronary intervention, and systolic
blood pressure. LBBB and non-LBBB patients were
divided into groups, deﬁned by 10-ms increments in
QRS duration. The 120- to 129-ms category was used as
the reference for Cox proportional hazards analysis,
and sex-by-treatment interactions were calculated
within the 10-ms subgroups. Kaplan-Meier curves for
the total population and separately in women and
men with LBBB and non-LBBB were used to assess
unadjusted comparisons of time-to-all-cause mortal-
ity in CRT-D patients across the 10-ms QRS duration
groups. Missing data were rare for all variables
(ranging between 0.02 and 0.61%) and were imputed
by using the most common value for categorical var-
iables and medians for continuous variables. All sta-
tistical analyses were conducted with SAS software,
version 9.3 (SAS Institute, Cary, North Carolina).
Ninety-ﬁve percent conﬁdence intervals are reported
for all hazard ratios, and probability values of less
than 0.05 were considered statistically signiﬁcant.
Probability values were not adjusted for multiplicity.
RESULTS
The ﬁnal study population included 31,892 CRT-D
patients, of whom 11,542 (36%) were women and
20,350 (64%) were men (Table 1). Women were more
likely than men to have LBBB (86% vs. 70%), normal
atrioventricular conduction (82% vs. 70%), and non-
ischemic cardiomyopathy (62% vs. 33%). Overall, the
majority of both women and men had New York Heart
Association (NYHA) functional class III heart failure
symptoms (84% and 82%).
After a median follow-up of 2.9 years (inter-
quartile range: 2.0 to 3.9 years), 5,428 patients(17%) died. In the overall cohort, those with LBBB
had a 24% lower mortality risk than those with
non-LBBB (adjusted hazard ratio [HR]: 0.76; 95%
conﬁdence interval [CI]: 0.72 to 0.80; p < 0.001).
Patients with QRS durations of 120 to 129 ms had
the highest mortality (Figure 1), with slightly better
survival in the QRS 130- to 139-ms (HR: 0.92; 95%
CI: 0.85 to 1.00; p ¼ 0.057) and 140- to 149-ms
groups (HR: 0.88; 95% CI: 0.81 to 0.96; p ¼ 0.002).
Survival was highest in patient groups with QRS of
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FIGURE 1 Kaplan-Meier Survival Curves by QRS Duration Among the Total Population
Curves reﬂect the survival probability of cardiac resynchronization therapy deﬁbrillator patients in 10-ms QRS duration groups. Multivariable
mortality hazard ratios (referenced to patients with QRS of 120 to 129 ms) are reported. CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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890150 ms or longer, with similar mortality in patients
with QRS of 150 to 159 ms (HR: 0.74; 95% CI: 0.67
to 0.80; p < 0.001), QRS of 160 to 169 ms (HR: 0.72;
95% CI: 0.66 to 0.79; p < 0.001), and QRS of 170 ms or
longer (HR: 0.69; 95% CI: 0.64 to 0.76; p < 0.001).
MORTALITY IN CRT-D PATIENTS BY SEX, QRS
MORPHOLOGY, AND DURATION. Overall, women
had an 18% lower mortality risk compared with men
(HR: 0.82; 95% CI: 0.78 to 0.87; p < 0.001). InSu
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B ¼ left bundle branch block.patients with LBBB, women had an adjusted 21%
lower mortality risk than men (HR: 0.79; 95% CI:
0.74 to 0.84; p < 0.001). Figure 2 shows unadjusted
survival curves for patients grouped by 10-ms QRS
intervals, stratiﬁed by sex and QRS morphology, and
the Central Illustration shows the hazard ratios for
mortality separately in women and men, comparing
QRS duration subgroups to a reference group with a
QRS duration of 120 to 129 ms. For both women andl in Men with LBBB
l in Men without LBBB
ollow-Up (Years)
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CENTRAL ILLUSTRATION Multivariable Hazard Ratios for Mortality in LBBB and non-LBBB QRS Duration Groups by Sex
Points reﬂect hazard ratios for all-cause mortality in LBBB (left) and non-LBBB (right) in 10-ms QRS duration groups for women and men. Lines
indicate 95% conﬁdence bounds. Sex-by-treatment interaction probability values are reported for every QRS duration category. See Online
Table 1 for exact numbers. LBBB ¼ left bundle branch block.
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891men with LBBB, mortality was highest in the QRS
120- to 129-ms group, with a slightly better survival
in QRS of 130 to 139 ms, although this did not reach
statistical signiﬁcance in either women or men. In
LBBB and QRS of 140 to 149 ms, women had a 27%
lower mortality than those with QRS of 120 to 129
ms (HR: 0.73; 95% CI: 0.60 to 0.88; p ¼ 0.001), and
this difference was 18% in men (HR: 0.82; 95% CI:
0.71 to 0.93; p ¼ 0.003); however, the difference
between sexes was not statistically signiﬁcant
(p ¼ 0.30 for interaction). With QRS duration longer
than 150 ms, the lower mortality risk remained sig-
niﬁcant within the 10-ms subgroups and was similar
between sexes (HR: 0.61 to 0.68; p < 0.001 for
women and HR: 0.58 to 0.66; p < 0.001 for men).
Although there were no signiﬁcant sex-by-treatment
interactions within the 10-ms QRS duration groups,
the HR point estimates for mortality remained fairly
consistent without much variation with QRS longer
than 140 ms in women and 150 ms in men (Central
Illustration).
In CRT-D patients without LBBB, there was no
difference in adjusted mortality risk between sexes
(HR: 0.96; 95% CI:0.86 to 1.06; p ¼ 0.36) and norelation between QRS duration and mortality (Central
Illustration). When all multivariable models were
repeated with adjustment for discharge medications,
the results did not change. The full multivariable
adjusted models can be found in the Online Appendix
(Online Tables 2 and 3 for women and men with LBBB
and Online Tables 4 and 5 for women and men
without LBBB).
DISCUSSION
In this large, real-world population of patients in the
NCDR ICD Registry with left ventricular systolic
dysfunction and predominantly NYHA functional
class III heart failure symptoms who were treated
with CRT-D, we found that women with LBBB have a
lower mortality risk than men with LBBB. Among all
patients with LBBB, longer QRS duration was associ-
ated with a better survival, although this lower mor-
tality risk plateaued at a QRS duration longer than
140 ms in women and longer than 150 ms in men. In
contrast, in the non-LBBB population, no sex-based
differences in mortality were found and mortality
risk was similar regardless of QRS duration. While in
FIGURE 3 Electrical Activation of the Ventricles in
Normal Conduction and LBBB
Sagittal view of ventricles in normal conduction (A) and LBBB
(B). Activation starts at the small arrows and spreads in a
wavefront with each line representing successive 10 ms. The
delay between activation of the interventricular septum and free
wall is only w40 ms in normal conduction, but w100 ms in
LBBB. Reproduced with permission from Strauss et al. (33).
LBBB ¼ left bundle branch block.
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892previous studies selected patient populations were
included and women were underrepresented, the
present analysis included a more diverse and real-
world CRT-D population with a larger proportion of
women.
SEX DIFFERENCES IN THE PHYSIOLOGY OF
DYSSYNCHRONY AND RESYNCHRONIZATION THERAPY.
Recent studies and meta-analyses have shown that
the presence of LBBB is predictive of a positive
response to CRT (6,23), whereas patients with
non-LBBB may experience no beneﬁt or even harm
from therapy (12,24–28). When the left bundle branch
is completely blocked, the left ventricular lateral wall
is activated approximately 100 ms later than the
interventricular septum due to the impairment of
electrical propagation in the rapidly conducting His-
Purkinje system (Figure 3). The left ventricular pac-
ing lead in CRT reduces this delay and resynchronizes
the activation between both walls, thereby improving
cardiac output and mechanical efﬁciency. In patients
without LBBB, the left ventricular activation via the
His-Purkinje system is rapid and considered normal.
For these reasons, CRT may be more effective in pa-
tients with LBBB than in patients without LBBB.
Because women have smaller ventricles and
shorter baseline QRS duration than men (17), they are
more likely to have a true LBBB compared with men,
who are more likely to have a false-positive LBBB
diagnosis at the lower end of the QRS duration pro-
longation spectrum (16). Single-center studies have
evaluated stricter LBBB criteria accounting for sex
differences in QRS duration, requiring a QRS of
130 ms or longer in women and 140 ms or longer in
men together with mid-QRS notching/slurring (16).
These studies found that patients who met these
stricter criteria have lower risks of heart failure hos-
pitalizations and mortality with CRT compared with
those not meeting the criteria (18,19).
In addition to these electrophysiological differ-
ences, other factors may contribute to the greater
response to CRT in women. Previous studies demon-
strated that ischemic cardiomyopathy and atrial
ﬁbrillation are associated with a worse prognosis in
CRT patients (12). In the present study, women indeed
had a lower rate of ischemic cardiomyopathy than
men, although patients with atrial ﬁbrillation were
excluded. Although the difference in the etiology of
left ventricular systolic dysfunction could have con-
tributed to the higher survival in women, our multi-
variable models controlled for this variable. In
addition, it is difﬁcult to separate the contribution of
LBBB and ischemic cardiomyopathy to the observed
outcomes as LBBB in CRT-D patients is usually caused
by nonischemic pathologies (29).The present ﬁndings complement the existing
literature addressing the relationship between CRT-D
and survival as a function of QRS morphology and
duration. A study from the NCDR ICD Registry found
that among patients receiving CRT-D, those with
LBBB and longest QRS duration had a lower mortality
risk than those without LBBB or shorter QRS duration
(25). Another study from the ICD Registry comparing
outcomes between patients receiving CRT-D with
those receiving ICD in a propensity-matched cohort
found the lowest rates of hospitalization for cardio-
vascular causes and heart failure with CRT in the
stratum of patients with LBBB and QRS duration
longer than 150 ms (30). However, in addition to
determining the relationship between sex and mor-
tality in groups according to QRS morphology and
duration, the present study evaluated mortality in
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Multiple clinical
factors should be considered when selecting candidates for car-
diac resynchronization therapy, including sex, QRS morphology,
and QRS duration.
TRANSLATIONAL OUTLOOK: The mechanisms responsible
for the differential response to cardiac resynchronization therapy
in women and men, which may include biological effects, patient
characteristics, or patient selection for device implantation,
require elucidation.
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89310-ms QRS duration groups, demonstrating that the
survival beneﬁt of CRT extends to shorter QRS dura-
tion groups among women as compared with men.
Interestingly, although a recently conducted meta-
analysis that also primarily included NYHA func-
tional class III heart failure patients found that
patients with QRS of 140 ms or longer beneﬁted from
CRT regardless of conduction type or sex (31), Multi-
center Automatic Deﬁbrillator Implantation Trial with
Cardiac Resynchronization Therapy (MADIT-CRT)
substudies found that women with QRS shorter than
150 ms, but not men with QRS shorter than 150 ms,
beneﬁted from therapy (8,28). Additionally, in the
recently published extended follow-up of MADIT-
CRT, it was found that the survival beneﬁt associ-
ated with CRT-D in patients with LBBB was
independent of QRS duration and did not differ by
sex; however, that analysis included fewer women
and primarily patients with NYHA functional class II
heart failure symptoms (32). Other published studies
of CRT effect, including QRS morphology and QRS
duration, have not performed separate analyses in
women and men (5,6,24,25).
STUDY LIMITATIONS. This study did not include an
ICD comparator group. Therefore, we were unable to
evaluate the true effectiveness of CRT-D therapy.
Multiple comparisons were performed; however, a
Bonferroni correction for the 10 comparisons in LBBB
women and LBBB men would not change the signiﬁ-
cance of the results (p < 0.005 for all LBBB). These
data only represent patients who were admitted for
the sole purpose of CRT-D implantation and did not
have a prior pacemaker or ICD. It is possible that entry
errors or missing data may have resulted in misdiag-
nosis of baseline characteristics, including QRS
morphology and QRS duration. However, extensive
data quality checks for the NCDR registries are in
place and previous work has demonstrated that the
participant average raw accuracy of data abstraction
for the NCDR ICD registry is approximately 91% (21).
The majority of patients in this cohort (83%) had
NYHA functional class III heart failure symptoms, and
thus the results are largely limited to that population.
The endpoint for this analysis was all-cause mortal-
ity; the exact cause of death was not known. Inaddition, this is an observational study in which there
is the possibility of confounding by unmeasured
variables, including noncardiac comorbidities; how-
ever, the most important potential confounders were
part of the baseline characteristics (QRS morphology,
QRS duration, ejection fraction, and NYHA heart
failure functional class).
CONCLUSIONS
This study demonstrated that among real-world
CRT-D recipients with predominantly NYHA func-
tional class III heart failure, mortality risk in women
with LBBB is lower than in men with LBBB, although
there is no risk difference between female and male
patients without LBBB. Furthermore, longer QRS
duration is associated with better survival in patients
with LBBB only. This favorable prognosis seems to
plateau with QRS longer than 140 ms in women and
150 ms in men. Differences in baseline characteristics,
patient selection for the procedure, and biological
effects of CRT therapy on left ventricular synchroni-
zation may contribute to the observed differences by
sex and QRS duration. Further studies comparing
CRT-D with a comparator ICD group may help eluci-
date these ﬁndings.
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